Are COVID Vaccine Stocks Buys As Trump Recovers?

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Judging by the high activity on the US Presidents Twitter account, it seems as if Donald Trump is feeling a bit better. Doctors have said that is health is improving, and he could be discharged today.

trump covid stock market tweet

The Coronavirus has already killed more than two hundred thousand Americans and has caused the economy to take a massive hit. However, the President’s quick recovery should be a boost for the stock market in general. Does his rate of recovery indicate that we may have this pandemic under control?

The Biotech stocks have been a leading indicator for markets since the onset of COVID-19. Now treatments created by companies Gilead Sciences, Inc. (NASDAQ: GILD) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) are both involved in President Trump’s treatment plan.

Watch the interview to see if you should trade the Coronavirus vaccine stocks on the back of this news.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.